scholarly journals Hepatitis C Virus Infection and Dialysis: 2012 Update

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Fabrizio Fabrizi

Hepatitis C virus infection is still common among dialysis patients, but the natural history of HCV in this group is not completely understood. Recent evidence has been accumulated showing that anti-HCV positive serologic status is significantly associated with lower survival in dialysis population; an increased risk of liver and cardiovascular disease-related mortality compared with anti-HCV negative subjects has been found. According to a novel meta-analysis (fourteen studies including 145,608 unique patients), the adjusted RR for liver disease-related death and cardiovascular mortality was 3.82 (95% CI, 1.92; 7.61) and 1.26 (95% CI, 1.10; 1.45), respectively. It has been suggested that the decision to treat HCV in patients with chronic kidney disease be based on the potential benefits and risks of therapy, including life expectancy, candidacy for kidney transplant, and co-morbidities. According to recent guidelines, the antiviral treatment of choice in HCV-infected patients on dialysis is mono-therapy but fresh data suggest the use of modern antiviral approaches (i.e., pegylated interferon plus ribavirin). The summary estimate for sustained viral response and drop-out rate was 56% (95% CI, 28–84) and 25% (95% CI, 10–40) in a pooled analysis including 151 dialysis patients on combination antiviral therapy (conventional or pegylated interferon plus ribavirin).

2021 ◽  
Vol 51 (1) ◽  
Author(s):  
José Daniel Bosia ◽  
María Virginia D´Ascenzo ◽  
Silvia Mabel Borzi ◽  
Ezequiel Barán ◽  
María Cecilia Calzona

The development of new direct acting antiviral drugs for the treatment of Hepatitis C virus infection, has made it possible to obtain an excellent cure rate and extend the indications for eradication of Hepatitis C virus to previously very difficult populations to treat like cystic fibrosis, in whom treatment with classic regimens based on pegylated Interferon plus ribavirin could favor worsening lung function. We present a case of a 41-year-old man with cystic fibrosis, diagnosed with Hepatitis C virus infection, genotype 1a, non-cirrhotic, treated with direct acting antiviral drugs for twelve weeks, obtaining a sustained viral response, without adverse effects. One year later, being on the waiting list, underwent a bipulmonary transplant.


Hematology ◽  
2011 ◽  
Vol 16 (2) ◽  
pp. 80-85 ◽  
Author(s):  
Marilza Campos‐de‐Magalhães ◽  
Carlos Eduardo Brandão‐Mello ◽  
Maria Lúcia Elias Pires ◽  
Maria Cecília da Fonseca Salgado ◽  
Selma Barcelo de Brito ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document